Negev Capital

Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods.

Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods.

Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.

BetterLife Pharma Inc. is a biotechnology company focused on developing and commercializing psychedelic products aimed at treating mental disorders across Canada, the United States, Australia, and the European Union. The company is also engaged in refining and developing drug candidates using a range of complementary interferon-based technologies, which are designed to stimulate the immune system against viral infections, including COVID-19 and human papillomavirus, as well as to directly target tumors for cancer treatment. Founded in 2002 and headquartered in Vancouver, Canada, BetterLife Pharma was previously known as Pivot Pharmaceuticals Inc. before rebranding in December 2019.

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.

Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods.

Reset Pharmaceuticals is a biotechnology company dedicated to developing and commercializing innovative psychedelic treatments for patients facing life-threatening illnesses, particularly cancer. The company's primary focus is on psilocybin combined with psychotherapy to address issues such as demoralization, anxiety, and depression in patients suffering from cancer. By leveraging advanced technology, Reset Pharmaceuticals aims to create therapeutics that not only improve mental health outcomes for terminal patients but also enhance their overall quality of life.

Mindstate Design Labs is a clinical-stage biotechnology company focused on developing innovative psychedelic-inspired therapeutics aimed at addressing intractable mental health conditions. By mapping the biological underpinnings of various psychedelic experiences, the company designs psychoactive effects intended for use in medically supervised environments. Their platform leverages a combination of natural history and computational methods to predict the acute effects of serotonergic agonists in humans. This allows healthcare institutions to effectively alter states of consciousness, facilitating the treatment of mental health disorders at their root.

Clairvoyant Therapeutics is a biotechnology company focused on advancing psychedelic therapy to improve patient outcomes. The company is dedicated to developing psilocybin drug therapies that aim to assist individuals struggling with substance use disorders and various mental health conditions. By employing a rapid clinical strategy, Clairvoyant Therapeutics seeks to bring innovative treatments to market, enabling patients to overcome their challenges and achieve healthier lives.

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

NanoPsy is a company that develops nanotechnology for theranostic applications to effectively improve psychedelic drug efficacy. Our patented nano technology which, in combination with our targeted delivery and controlled dosing technology methods, will allow for an increase in solubility/absorption of these molecules. Thus a more efficacious API.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

WeSana Health is a life sciences company focused on the advancement of psilocybin-based medicine. Founded in 2020 by Daniel Carcillo, the company is headquartered in Homer Glen, Illinois. WeSana Health is actively exploring new business opportunities to further its mission in the burgeoning field of psychedelics, aiming to develop innovative therapeutic solutions for various mental health conditions.